Stereotactic radiosurgery: a meta-analysis of current therapeutic applications in neuro-oncologic disease
- PMID: 21152953
- DOI: 10.1007/s11060-010-0360-0
Stereotactic radiosurgery: a meta-analysis of current therapeutic applications in neuro-oncologic disease
Abstract
Stereotactic radiosurgery (SRS) represents an important tool in neurosurgery and radiotherapy for addressing a multitude of diseases, most notably in the field of neuro-oncology. The pathologies for which it is employed vary significantly, and few controlled studies exist to evaluate its efficacy. We aimed to provide a quantitative meta-analysis of SRS applications in neuro-oncology, providing benchmarks for expected outcomes. The meta-analysis was conducted in accordance with established standards for evaluating observational data. Specific inclusion criteria were utilized, search terms recorded, and data extracted to summarize demographic and outcome statistics. Meta-analysis was conducted where statistically appropriate, and clinical outcomes summarized as tumor stability, survival, and complications in a pathology-specific manner. For vestibular schwannoma, 37 studies with a total 3,677 patients were included. Overall disease stabilization rate after adjustment for significant publication bias was 91.1%. Non-cranial nerve complication rate after publication bias adjustment was 5.6%. Accounting for publication bias, rate of hearing preservation was with 59.3%. For 456 glioblastoma multiforme (GBM) patients in 11 studies receiving SRS, median survival from diagnosis was 13.5-26 months, while overall complication rate was 11.4%. For meningioma, 15 studies with a total 2,734 patients were included; 77.1% were classified as skull base. Overall disease stabilization rate was 89.0, while overall complication rate was 7.0%. For metastatic disease, 27 studies with a total of 2,679 patients were included. Overall median survival from time of SRS was 5-14 months, overall 1-year survival rates were 15-54.9%, while reported local disease control rates were 59.6-96.8%. Stereotactic radiosurgery is an increasingly important tool in the management of neuro-oncologic diseases. While there is a pathology-specific role for SRS, current data show excellent results in treating several pathologies. As such, SRS adds significantly to the neurosurgical armamentarium for treating neuro-oncologic processes.
Similar articles
-
Role of adjuvant or salvage radiosurgery in the management of unresected residual or progressive glioblastoma multiforme in the pre-bevacizumab era.J Neurosurg. 2015 Apr;122(4):757-65. doi: 10.3171/2014.11.JNS13295. Epub 2015 Jan 16. J Neurosurg. 2015. PMID: 25594327
-
A matched cohort comparison of clinical outcomes following microsurgical resection or stereotactic radiosurgery for patients with small- and medium-sized vestibular schwannomas.J Neurosurg. 2016 Dec;125(6):1472-1482. doi: 10.3171/2015.12.JNS151857. Epub 2016 Apr 1. J Neurosurg. 2016. PMID: 27035174
-
Potential role for LINAC-based stereotactic radiosurgery for the treatment of 5 or more radioresistant melanoma brain metastases.J Neurosurg. 2015 Nov;123(5):1261-7. doi: 10.3171/2014.12.JNS141919. Epub 2015 Jul 3. J Neurosurg. 2015. PMID: 26140482
-
Stereotactic radiosurgery versus stereotactic radiotherapy in the management of intracranial meningiomas: a systematic review and meta-analysis.Neurosurg Focus. 2019 Jun 1;46(6):E2. doi: 10.3171/2019.3.FOCUS1970. Neurosurg Focus. 2019. PMID: 31153149
-
Therapeutic Role of Gamma Knife Stereotactic Radiosurgery in Neuro-Oncology.Mo Med. 2020 Jan-Feb;117(1):33-38. Mo Med. 2020. PMID: 32158047 Free PMC article. Review.
Cited by
-
The Long and Winding Road: From the High-Affinity Choline Uptake Site to Clinical Trials for Malignant Brain Tumors.Adv Pharmacol. 2016;76:147-73. doi: 10.1016/bs.apha.2016.03.002. Epub 2016 Apr 23. Adv Pharmacol. 2016. PMID: 27288077 Free PMC article. Review.
-
Efficacy and comorbidities of hypofractionated and single-dose radiosurgery for vestibular schwannomas: a systematic review and meta-analysis.Neurooncol Pract. 2021 Feb 1;8(4):391-404. doi: 10.1093/nop/npab009. eCollection 2021 Aug. Neurooncol Pract. 2021. PMID: 34277018 Free PMC article. Review.
-
Evolutionary basis of a new gene- and immune-therapeutic approach for the treatment of malignant brain tumors: from mice to clinical trials for glioma patients.Clin Immunol. 2018 Apr;189:43-51. doi: 10.1016/j.clim.2017.07.006. Epub 2017 Jul 15. Clin Immunol. 2018. PMID: 28720549 Free PMC article. Review.
-
National trends in inpatient admissions following stereotactic radiosurgery and the in-hospital patient outcomes in the United States from 1998 to 2011.J Radiosurg SBRT. 2016;4(3):165-176. J Radiosurg SBRT. 2016. PMID: 27795870 Free PMC article.
-
Management of intracranial meningiomas in Enugu, Nigeria.Surg Neurol Int. 2012;3:110. doi: 10.4103/2152-7806.101788. Epub 2012 Sep 28. Surg Neurol Int. 2012. PMID: 23087826 Free PMC article.
References
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Research Materials